The Effect of Adenomyosis in Myometrial Invasion and Overall Survival in Endometrial Cancer

Selçuk Erkilinç, Erkilinç S, Selçuk Erkılınç, Enes Taylan, Varol Gülseren, Gamze Erkılınç, Gamze Erkilinç, Erkilinç G, Tuğba Karadeniz, Karadeniz T, Mustafa Bağcı, Mustafa Bağci, Bağci M, Orhan Temel, Temel O, Solmaz U, Ulaş Solmaz, Gökçü M, Mehmet Gökçü, Muzaffer Sanci, Muzaffer Şancı
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2017 · vol. 28(1) , pp. 145–151 · doi:10.1097/igc.0000000000001137 · PMID:29040186 · W2765343814
article OA: closed CC0 ⤵ 14 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This study investigated the impact of adenomyosis on myometrial invasion and the overall survival rates of patients diagnosed with endometrial cancer.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

AimThe aim of this study was to evaluate whether adenomyosis had an effect on myometrial tumor invasion, stage of the disease, and survival in endometrial cancer.MethodsEndometrial cancer patients encountered between 2007 and 2016 were identified from pathology records. Patients who underwent suboptimal surgical or medical treatment or with insufficient clinical or surgical data were excluded. Patients diagnosed as having concurrent adenomyosis constituted the study group. Control group patients were randomly selected in a paired design according to the tumor grades in the study group, and for each tumor grade, 4 times as many as patients were included. Tumor stage, histologic type and grade, myometrial invasion, lymphovascular space invasion, presence and location of the adenomyosis in myometrial wall, distance from endometrial line, tumor in adenomyosis, adjuvant treatment, and relapse were primary outcomes.Age, body mass index, medical comorbidities, and type of operation were also recorded. Univariate and multivariate Cox proportional hazards regression models were performed for overall survival.ResultsOf those 1242 endometrial cancer patients, 80 with concurrent adenomyosis were identified and compared with 320 patients without adenomyosis following a paired selection based on tumor grade. Higher rates of myometrial invasion, lymphovascular space invasion, tumor diameter, and adjuvant treatments were found in the nonadenomyosis group compared with adenomyosis group (P ≤ 0.001). In patients with adenomyosis, rates of early-stage disease and overall survival were significantly higher compared with the control group (P = 0.001 and 0.01, respectively).ConclusionsOur results showed that adenomyosis is significantly associated with lower stage in endometrial cancer that may suggest a possible limiting effect on endometrial cancer spread. In addition, despite similar rates in disease-free survival and endometrial cancer-related death, overall survival rate was significantly higher in the presence of adenomyosis and might be considered as a good prognostic factor for endometrial cancer.

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

Adenomyosis Endometrial Neoplasms Myometrium Adenomyosis Adenomyosis Carcinoma, Endometrioid Carcinoma, Endometrioid Carcinoma, Endometrioid Cohort Studies Endometrial Neoplasms Endometrial Neoplasms Female Humans Kaplan-Meier Estimate Middle Aged Myometrium Neoplasm Invasiveness Retrospective Studies

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (29)

Cited by (15)

Source provenance

europepmc
last seen: 2026-07-26T06:08:39.051465+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:20:13.663096+00:00
License: CC0 · commercial use OK